ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: cancer

New Drug Approvals Hit 21-Year High in 2017

Ben Hirschler  |  

LONDON (Reuters)—U.S. drug approvals hit a 21-year high in 2017, with 46 novel medicines winning a green light—more than double the previous year—while the figure also rose in the European Union. The European Union (EU) recommended 92 new drugs, including generics, up from 81; and China laid out plans to speed up approvals in what…

Vitamin D, Calcium Supplements May Not Lower Fracture Risk

Lisa Rapaport  |  

(Reuters Health)—Older adults who take vitamin D and calcium are no less likely to break their hips or other bones than peers who don’t use these supplements, a research review suggests. Researchers examined data from 33 previous trials with a total of more than 51,000 people aged 50 or older who were living in the…

Rituximab Use Increasing in Treatment of Pediatric Vasculitis

Catherine Kolonko  |  

According to a large cohort study of pediatric patients, rituximab use is on the rise in the treatment of children diagnosed with vasculitis. Treatment with cyclophosphamide remains common, but it’s beginning to wane. Dialysis and mechanical ventilation also remain common, the study indicates. The retrospective study of hospitalized children in the U.S. included the largest…

Long-Term Benefits, Risks of Biologic Disease-Modifying Anti-Rheumatic Drugs in Patients with RA

Nan Yang, PharmD, & Kurt Oelke, MD, on behalf of the ARHP Practice Committee  |  

Two decades have passed since the first biologic disease-modifying anti-rheumatic drug (bDMARD) was approved. Studies on the long-term use of biologics in different disease states, such as for cardiovascular disease (CVD) and malignancy, as well as for knee/hip replacement, reveal some encouraging news. In clinical trials, bDMARDs have been shown to increase the risk of…

Fellows’ Forum Case Report: Necrotizing Autoimmune Myopathy

Shivani Garg, MD, Suzana Alex John, MD, & Frehiywot Ayele, MD  |  

Necrotizing autoimmune myopathy (NAM) is a relatively recently discovered subgroup of inflammatory myopathies. NAM is characterized by predominant muscle fiber necrosis and regeneration with little or no inflammation.1 One subgroup of NAM is 3-hydroxy-3-methylglutaryl-CoA reductase antibody (HMGCR Ab)-related immune-mediated necrotizing myopathy (IMNM), which occurs (rarely) after statin exposure, with a rough incidence of two per…

With No Deal on Children’s Health Plan, U.S. States Scramble for Plan B

Jilian Mincer and Yasmeen Abutaleb  |  

NEW YORK/WASHINGTON (Reuters)—For Nancy Minoui of Portland, Oregon, and Crystal Lett of Dublin, Ohio, Congress’ failure to fund the Children’s Health Insurance Program is not some distant tale of political wrangling. For Minoui, it’s about how to provide care for her daughter, Marion Burgess, born last Valentine’s Day with a hole in her heart. For…

Social Media May Help Chronically Ill Connect to Doctors, Fellow Patients

Mary Gillis  |  

(Reuters Health)—Social media groups that bring together patients, family, friends and healthcare providers can improve patients’ outlook and reduce their anxiety and depression, a recent U.S. study suggests. In a nine-month experiment with liver-transplant patients, researchers found that participants came to rely heavily on a closed Facebook group, both for information about their condition and…

Older Women Should Not Take Hormones to Prevent Chronic Diseases

Will Boggs MD  |  

(Reuters Health)— Postmenopausal women should not use hormone therapy to prevent chronic medical conditions, because the risk of significant side effects outweighs the unclear evidence of a benefit, according to a government-backed panel of experts. Most chronic conditions – coronary heart disease, dementia, stroke, fractures, and breast cancer, for example – are more common with…

Year in Review: Expert Covers 2017’s Key Clinical Findings

  |  

In a Year in Review session at the 2017 ACR/ARHP Annual Meeting, Daniel Solomon, MD, MPH, highlighted the latest and most intriguing aspects of clinical research on rheumatic diseases from 2017. His discussion touched on medical therapy, genetics, the effects of bariatric surgery and diet, cancer risk and more…

Rheumatology Drug Updates: Efficacy Studied Following Accelerated Drug Approvals; Plus Secukinumab Meets Benchmark for Psoriasis

  |  

Medications for serious or life-threatening conditions may receive accelerated approval from the U.S. Food and Drug Administration (FDA) by showing an effect on surrogate measures that are reasonably likely to predict a treatment’s clinical benefit. Post-approval confirmatory drug trials are then required to determine whether or not these effects translate into clinical improvements. In recent…